Kellie Zeichner Speaks to the Power of Standardized Monitoring Procedures for Patients With Rare Tumors
Kellie Zeichner BSN, RN, OCN, explains how her institution created a standardized monitoring procedure for insulinoma care.
Oncology Drug Crash Course: Fam-Trastuzumab Deruxtecan-Nxki (Enhertu)
After demonstrating significant efficacy as a third-line treatment for patients with metastatic HER2-positive breast cancer, fam-trastuzumab deruxtecan-nxki has gained approval from the FDA for 5 indications and is under investigation across solid tumors.
Following Reconstruction, Patients With Early Breast Cancer May Safely Opt For a Shorter Course of Radiation Therapy
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
2 Clarke Drive Cranbury, NJ 08512